Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
|
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America
    Jamotte, Aurelien
    Clay, Emilie
    Macabeo, Berengere
    Caicedo, Andres
    Guillermo Lopez, Juan
    Bricks, Lucia
    Romero Prada, Martin
    Marrugo, Ruben
    Alfonso, Pamela
    Moreno Arevalo, Brechla
    Franco, Danilo
    Garcia Diaz, Lourdes
    Isaza de Molto, Yadira
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (04) : 877 - 888
  • [22] A new decade, a new seasonal influenza: the Council of the European Union Recommendation on seasonal influenza vaccination
    Nicoll, A.
    EUROSURVEILLANCE, 2010, 15 (01): : 4 - 5
  • [23] Motivators for the public to receive the seasonal influenza vaccination and the effect of coronavirus disease 2019 pandemic on the uptake of the seasonal influenza vaccination
    Alamer, Naheel A.
    Al-Shammari, Malak A.
    Al-Johani, Wejdan M.
    Al-Mansour, Abdulelah H.
    Alshamlan, Nouf A.
    Alqarni, Amani M.
    Aldhawyan, Adam F.
    Alkaltham, Shikha M.
    Al-Muhaidib, Hala R.
    Darwish, Magdy A.
    JOURNAL OF FAMILY AND COMMUNITY MEDICINE, 2024, 31 (01): : 9 - 15
  • [24] AN ECONOMIC MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF VACCINATION OF SENIORS WITH FLUZONE HIGH DOSE INFLUENZA VACCINE IN AUSTRALIA
    Largeron, N.
    Manton, A.
    Net, P.
    Choi, S.
    Becker, D. L.
    Bianic, F.
    Jacob, J.
    Maschio, M.
    VALUE IN HEALTH, 2018, 21 : S65 - S65
  • [25] The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly
    Blank, Patricia R.
    Schwenkglenks, Matthias
    Szucs, Thomas D.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (03) : 318 - 325
  • [26] Establishing the health and economic impact of influenza vaccination within the European Union 25 countries
    Ryan, James
    Zoellner, York
    Gradl, Birgit
    Palache, Bram
    Medema, Jeroen
    VACCINE, 2006, 24 (47-48) : 6812 - 6822
  • [27] Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    Lisa J McGarry
    Keith P Klugman
    David R Strutton
    Kristen E Gilmore
    Milton C Weinstein
    BMC Infectious Diseases, 10
  • [28] Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Rubin, Jaime L.
    McGarry, Lisa J.
    Klugman, Keith P.
    Strutton, David R.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [29] Vaccination of Healthy Children Against Seasonal Influenza A European Perspective
    Heikkinen, Terho
    Tsolia, Maria
    Finn, Adam
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (08) : 881 - 888
  • [30] Seasonal Influenza Vaccination and Recommendation: The Difference between General Practitioners and Public Health Workers in China
    Rong, Hongguo
    Lai, Xiaozhen
    Ma, Xiaochen
    Hou, Zhiyuan
    Li, Shunping
    Jing, Rize
    Zhang, Haijun
    Peng, Zhibin
    Feng, Luzhao
    Fang, Hai
    VACCINES, 2020, 8 (02)